Ascendis Pharma A/S
ASND
167 hedge funds and large institutions have $5.88B invested in Ascendis Pharma A/S in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 59 reducing their positions, and 31 closing their positions.
97% more call options, than puts
Call options by funds: $28.2M | Put options by funds: $14.3M
2.11% more ownership
Funds ownership: 108.87% → 110.98% (+2.1%)
0% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 59
6% less funds holding
Funds holding: 177 → 167 (-10)
6% less funds holding in top 10
Funds holding in top 10: 16 → 15 (-1)
19% less capital invested
Capital invested by funds: $7.27B → $5.88B (-$1.4B)
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$147M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$100M |
| 3 |
Janus Henderson Group
London,
|
+$42M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$29.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$105M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$69.7M |
| 3 |
EP
Eversept Partners
New York
|
-$49M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$40M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$27.9M |
ASND Hedge Fund Activity: Q2 2022 in Review
167 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2022, worth a combined $5.88B — down 19% from $7.27B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ASND and 23 opened new positions — a net loss of 8 holders — while 59 trimmed existing stakes and 59 added.
The largest buyer was Goldman Sachs, adding an estimated $147M. The largest seller was Wellington Management Group, cutting an estimated $105M.
- 167 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2022, down from 177 in Q1 2022.
- Funds reported $5.88B of Ascendis Pharma A/S stock for Q2 2022, down 19% quarter-over-quarter.
- 23 funds opened new Ascendis Pharma A/S positions in Q2 2022 and 31 closed out, a net change of -8 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2022 was Goldman Sachs, an estimated $147M added.
- The largest Ascendis Pharma A/S seller in Q2 2022 was Wellington Management Group, an estimated $105M sold.
Based on aggregated 13F filings for Q2 2022.